… recommendations for use of DOACs in the obese population 1 , data from clinical … in obese
patients are limited. We reviewed the available data on the use of DOACs in obese patients …

… The strengths of this study included enrolling only morbidly obese patients with BMI > 40
kg/m 2 , separately evaluating patients with BMI > 50 kg/m 2 , and separately analyzing the …

… In clinical practice, direct oral anticoagulants (DOACs) are … of patients with venous
thromboembolism are also obese. … doses in patients with obesity up to a body mass index (BMI) of …

… a million extremely obese individuals in the US for whom a decision may be needed regarding
whether to use a direct oral anticoagulant (DOAC) or warfarin for anticoagulation. Clearly, …

… anticoagulation with the direct oral anticoagulants (DOACs) in morbidly obese patients. We
… in patients with either a body-mass index (BMI) over 40 kg/m2 and/or a weight over 120 kg. …

… obese patients. Studies that describe the use of direct oral anticoagulants (DOACs) in obese
patients … (PD) studies of DOACs in obese patients showed a modest effect on PK parameters…

… current cardioversion for AF or atrial flutter among patients with BMI > 40 kg/m 2 on DOACs
… to morbidly obese patients exist. In this context, we sought to study obese patients that …

… of obese patients, particularly those with morbid obesity, … direct oral anticoagulants in these
cohorts of patients. None of the RCTs reported the results of patients with morbid obesity (BMI …

… in obesity, available PK/PD, and clinical data on DOACs use in morbidly obese patients
with … AF; (2) obese patients and/or morbidly obese patients. We then thoroughly screened …

… -analysis results in morbidly obese patients with AF. Direct oral anticoagulants (DOACs)
have been shown to be equally effective or superior to warfarin in patients with atrial fibrillation (…